9851 related articles for article (PubMed ID: 1532109)
1. Tumor eradication by adoptive transfer of cytotoxic T lymphocytes.
Melief CJ
Adv Cancer Res; 1992; 58():143-75. PubMed ID: 1532109
[No Abstract] [Full Text] [Related]
2. Adoptive immunotherapy with recombinant interleukin 2, LAK and TIL.
Kurnick JT; Kradin RL
Allergol Immunopathol (Madr); 1991; 19(5):209-14. PubMed ID: 1811418
[No Abstract] [Full Text] [Related]
3. Circumvention of tumor cell escape following specific immunotherapy.
Frost P; Bonavida B
Cancer Biother Radiopharm; 2000 Apr; 15(2):141-52. PubMed ID: 10803319
[No Abstract] [Full Text] [Related]
4. Cytotoxic T lymphocyte therapy of cancer and tumor escape mechanisms.
Melief CJ; Kast WM
Semin Cancer Biol; 1991 Oct; 2(5):347-54. PubMed ID: 1773050
[TBL] [Abstract][Full Text] [Related]
5. Finding a place for tumor-specific T cells in targeted cancer therapy.
Riddell SR
J Exp Med; 2004 Dec; 200(12):1533-7. PubMed ID: 15611285
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 2 in cancer therapy.
Testa U; Montesoro E; Bulgarini D; Samoggia P; Masciulli R; Habetswallner D; Carè A; Mariani G; Giannella G; Boccoli G
Ann Ist Super Sanita; 1990; 26(3-4):283-334. PubMed ID: 2091501
[TBL] [Abstract][Full Text] [Related]
7. Adoptive immunotherapy of cancer using activated autologous lymphocytes--current status and new strategies.
Yamaguchi Y; Ohshita A; Kawabuchi Y; Ohta K; Shimizu K; Minami K; Hihara J; Miyahara E; Toge T
Hum Cell; 2003 Dec; 16(4):183-9. PubMed ID: 15147038
[TBL] [Abstract][Full Text] [Related]
8. T-cell-associated cellular immunotherapy for lung cancer.
Li K; Zhang Q; Zhang Y; Yang J; Zheng J
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1249-58. PubMed ID: 25381064
[TBL] [Abstract][Full Text] [Related]
9. An explanation of the variable clinical response to interleukin 2 and LAK cells.
Parmiani G
Immunol Today; 1990 Apr; 11(4):113-5. PubMed ID: 2187466
[TBL] [Abstract][Full Text] [Related]
10. Strategies of lymphocyte activation for the adoptive immunotherapy of metastatic cancer: a review.
Strome SE; Krauss JC; Chang AE; Shu S
J Hematother; 1993; 2(1):63-73. PubMed ID: 7921967
[No Abstract] [Full Text] [Related]
11. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
[TBL] [Abstract][Full Text] [Related]
12. [Our experience with lymphocytes activated against cancer: CTL cells].
Marcellino LR; Vinciguerra M; Marcellino MV; Sessa E
G Chir; 1997 Oct; 18(10):605-7. PubMed ID: 9479972
[TBL] [Abstract][Full Text] [Related]
13. Is antigen specificity the key to efficient adoptive T-cell therapy?
Labarriere N; Khammari A; Lang F; Dreno B
Immunotherapy; 2011 Apr; 3(4):495-505. PubMed ID: 21463191
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocytes from human solid tumors: antigen-specific killer T lymphocytes of activated natural killer lymphocytes.
Whiteside TL; Heo DS; Takagi S; Herberman RB
Immunol Ser; 1989; 48():139-57. PubMed ID: 2488318
[No Abstract] [Full Text] [Related]
15. Tumor-derived activated cells: culture conditions and characterization.
Maleckar JR; Friddell CS; Lewko WM; Yannelli JR; West WH; Oldham RK
Immunol Ser; 1989; 48():159-73. PubMed ID: 2488319
[No Abstract] [Full Text] [Related]
16. Adoptive immunotherapy of a syngeneic murine leukemia with a tumor-specific cytotoxic T cell clone and recombinant human interleukin 2: correlation with clonal IL 2 receptor expression.
Matis LA; Shu S; Groves ES; Zinn S; Chou T; Kruisbeek AM; Rosenstein M; Rosenberg SA
J Immunol; 1986 May; 136(9):3496-501. PubMed ID: 2420893
[TBL] [Abstract][Full Text] [Related]
17. [Generation and activation of tumor-infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK-TIL therapy) in patients with advanced breast and ovarian carcinoma].
Mallmann P; Krebs D
Gynakol Geburtshilfliche Rundsch; 1995; 35 Suppl 1():161-5. PubMed ID: 8672919
[TBL] [Abstract][Full Text] [Related]
18. Adoptive cellular immunotherapy of cancer.
Winter H; Fox BA
Curr Opin Mol Ther; 1999 Feb; 1(1):89-97. PubMed ID: 11249690
[No Abstract] [Full Text] [Related]
19. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
[TBL] [Abstract][Full Text] [Related]
20. [Cell therapy in solid tumors].
Ravaud A
Bull Cancer; 2001 Jan; 88(1):91-100. PubMed ID: 11182658
[No Abstract] [Full Text] [Related]
[Next] [New Search]
